Lennerz 2014.

Methods	Randomized phase I
Participants	49 participants with survivin expressing solid tumours (ovarian cancer n = 7)
Interventions	Three dosage groups of EMD640744 vaccine (5 HLA class I‐binding survivin peptides in Montanide ISA 62 VG)
Outcomes	Immune response Safety Clinical response
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised between 3 dosage groups
Allocation concealment (selection bias)	Unclear risk	Randomised trial
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open‐label study
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Low risk	No other forms of bias detected